

Special Issue

Pharmacotherapy in the Era of Pandemics: Latest Advances and Prospects

Message from the Guest Editors

Medications should not be considered as static elements or isolated from the physiological phenomena of the human body or their interaction with other medications. They are dynamic tools, with effects that can be modified by multiple factors and whose use must be balanced to optimize the therapeutic objectives sought and to avoid unwanted effects. Additionally, their use should also be supervised by specialists. These are difficult times, times in which the emergence of pathogens potentially capable of spreading to produce pandemics makes the sound of war drums, in which medicines are invaluable. In essence, drugs can act both at the level of prevention and treatment. The sudden emergence of unknown pathogens capable of producing diseases that we are not capable of curing or even alleviating at the time we detect them undoubtedly forces us to investigate to promote the development of these types of drugs. In this Special Issue, all papers will present research on drugs used in emerging infectious or non-infectious diseases, their mechanisms of action, interaction with other drugs or repositioning of drugs not used for their intended use in these diseases.

Guest Editors

Dr. Antonio Gutiérrez-Pizarraya

Dr. Dorota Kopciuch

Dr. Anna Paczkowska

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/129599

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).